1st-line mFOLFOXIRI plus panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109)M. Geissler, T. Klingler,J. Riera Knorrenschild,Andrea Tannapfel, J. Greeve,T. Seufferlein,S. Kanzler,S. Held,Volker Heinemann,Anke Reinacher-Schick,U. M. MartensANNALS OF ONCOLOGY(2018)引用 5|浏览26暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要